Paratek Pharmaceuticals Inc. PRTK

NAS: PRTK | ISIN: US6993743029 20/09/2023

2,230 USD (+1,83%)

(+1,83%) 20/09/2023

Toon enkel gratis nieuws

11 juli 2023 · NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital · Persbericht

27 juni 2023 · NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital · Persbericht

30 september 2021 · Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 · Persbericht

5 augustus 2021 · Acurx Pharmaceuticals Joins the Antimicrobials Working Group · Persbericht

8 juni 2021 · Crestone Joins Antimicrobials Working Group · Persbericht

1 maart 2021 · Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

24 februari 2021 · Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million · Persbericht

18 februari 2021 · Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference · Persbericht

17 februari 2021 · Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 · Persbericht

1 februari 2021 · Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 januari 2021 · Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe